About Stealth BioTherapeutics
Stealth BioTherapeutics is a Healthcare company based in Newton (United States) founded in 2007, and was acquired by Morningside in August 2022. Developer of peptide therapy to treat rare mitochondrial diseases and its dysfunction-related disorders. Stealth BioTherapeutics has raised $100 million across 2 funding rounds from investors including CMBC Capital, Morningside and Atlantis Investment. The company has 31 employees. Its chief executive, as recorded, is Reenie McCarthy. Its website stealthbt.com draws about 12 thousand monthly visits. Stealth BioTherapeutics offers products and services including Elamipretide. Its focus areas include Life Sciences, Rare Diseases, Drugs and Diversified. Its legal entity is STEALTH BIOTHERAPEUTICS INC. Its competitors include Moderna, BridgeBio and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2007 and based in Newton, United States, the biotechnology company is engaged in developing peptide therapies for rare mitochondrial diseases and associated dysfunctions. Mitochondrial Carrier Technology is employed to deliver active candidates to mitochondria. The lead product, Elamipretide, functions as a tetrapeptide that stabilizes cardiolipin, thereby supporting electron transfer and inhibiting apoptosis. Applications are targeted at skeletal, ocular, and cardiorenal conditions stemming from mitochondrial impairment.
- Headquarters Newton, United States
- Employees 31
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website stealthbt.com
- Social LinkedIn X
- Acquired by Morningside (Aug 2022)
- Legal Name Stealth Biotherapeutics Inc.
- Total Equity Funding$100M (USD)
in 2 rounds
- Latest Funding Round$20M (USD), Post-IPO
Apr 2020
- InvestorsCMBC Capital
& 7 more
- Employee Count31
- Acquired byMorningside
(Aug 2022)
Products & Services of Stealth BioTherapeutics
Stealth BioTherapeutics offers a comprehensive portfolio of products and services, including Elamipretide.
Investigational therapy to restore mitochondrial function in diseases.
Funding Insights of Stealth BioTherapeutics
Stealth BioTherapeutics has successfully raised a total of $100M across 2 strategic funding rounds. The most recent funding activity was a Post-IPO round of $20 million completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $100M
- Total Rounds 2
- Last Round Post-IPO — $20M
- First Round $100M
(Jan 2018)
- Investors Count 8
All 2 funding rounds of Stealth BioTherapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2020 | $20M | Post-IPO | – | – | |
| Jan 2018 | $100M | Private Equity Round | – | Nan Fung Life Sciences |
8 investors in total: 8 institutional.
Investors in Stealth BioTherapeutics
Stealth BioTherapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include CMBC Capital, Morningside and Atlantis Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors are invested in by Morningside, a VC fund. | morningside.com | Newton, United States | ||
VC firm funding companies in China and the US | bvcf.com | Huangpu, China | ||
Private equity investments are focused on life science companies. | sagainv.com | Beijing, China | ||
Corporate backed venture capital firm investing in life sciences sector | nanfunglifesciences.com | San Francisco, United States | ||
Atlantis Investment is focused on Asian equity investment strategies. | 1994 | atlantis-investment.com | Hong Kong, Hong Kong SAR | |
Diversified financial institution | 1998 | cmbccap.com | Hong Kong, China | |
Provides alternative investment management services as a SEC-regulated advisory firm. | 1983 | kingdon.com | New York, United States | |
| oceanequitygroup.com |
Investor details for Stealth BioTherapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Stealth BioTherapeutics
25 people are tracked at Stealth BioTherapeutics (18 in leadership, 7 in team); the tracked headcount is 31.
| Name | Role | Group |
|---|---|---|
Reenie McCarthy | CEO | Leadership |
Shahista Whooley | Associate Director, Clinical Development (ophthalmology) | Leadership |
Jim Carr | Chief Clinical Development Officer | Leadership |
Henry Hess | Chief Legal Counsel | Leadership |
Mike Malynn | Chief People Officer | Leadership |
Brian Saxton | VP, Quality Assurance | Leadership |
James D. Wakefield | Senior Director, Clinical Pharmacology And DMPK | Leadership |
Donna Cowan | Director Expanded Access Programs & Registry | Leadership |
Amy Meadowcroft | Executive Director, Clinical Development | Leadership |
Gene Kelly | Executive Director Medical Affairs | Leadership |
Anthony Abbruscato | VP, Clinical Development | Leadership |
Brian Blakey | Chief Business Officer | Leadership |
Justin Perry | Associate Director, New Product Planning, Business Development And Alliance Management | Leadership |
James Carr | Chief Clinical Development Officer | Leadership |
Mitesh Chauhan | Associate Director | Leadership |
Guo Zhu Zheng | Executive Director | Leadership |
Anne Rees | Director, GMP QA | Leadership |
Yunmi Park | Associate Director, Non-clinical Program Management | Leadership |
Jason May | V.p. Finance & Accounting | Team |
Margaret Perkins | Product Launch Manager | Team |
5 more people are available in the full profile.
Complete people profiles for Stealth BioTherapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Stealth BioTherapeutics
5 dated milestones of Stealth BioTherapeutics across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Stealth BioTherapeutics is founded.
- Funding First funding round of $100.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $20.0M.
- Exit Acquired by Morningside.
Competitors of Stealth BioTherapeutics
Stealth BioTherapeutics has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of Stealth BioTherapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Stealth BioTherapeutics
The website of Stealth BioTherapeutics (stealthbt.com) receives about 11.9K visits a month and ranks #2,163,428 among all websites worldwide, #2,939 in Biotechnology and Pharmaceuticals.
- Monthly visits11.9K
▲ 13.6% vs previous month
- Unique visitors4.9K
per month
- Global rank#2,163,428
among all websites
- Category rank#2,939
Health · Biotechnology and Pharmaceuticals
- Bounce rate35%
- Pages per visit1.8
- Average visit23 sec
- DevicesDesktop 31% · Mobile 69%
Websites whose visitors overlap most with Stealth BioTherapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| timebioventures.com | 100% | #6,914,627 | View details |
Top companies in Rare Diseases
3 companies that operate in the same segment as Stealth BioTherapeutics (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Stealth Biotherapeutics
Complete news archive for Stealth BioTherapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Stealth BioTherapeutics
Stealth BioTherapeutics was founded in 2007 and raised its 1st funding round 11 years after it was founded.
Stealth BioTherapeutics is headquartered in Newton, United States. It is registered at Newton, Massachusetts, United States.
Reenie McCarthy is the CEO of Stealth BioTherapeutics, as recorded in our data.
Stealth BioTherapeutics is a funded company, having raised a total of $100M across 2 funding rounds to date. The company's 1st funding round was a Private Equity Round of $100M, raised on Jan 2018.
Stealth BioTherapeutics has 31 employees.
Founded in 2007 and based in Newton, United States, the biotechnology company is engaged in developing peptide therapies for rare mitochondrial diseases and associated dysfunctions. Mitochondrial Carrier Technology is employed to deliver active candidates to mitochondria. The lead product, Elamipretide, functions as a tetrapeptide that stabilizes cardiolipin, thereby supporting electron transfer and inhibiting apoptosis. Applications are targeted at skeletal, ocular, and cardiorenal conditions stemming from mitochondrial impairment.
Stealth BioTherapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Stealth BioTherapeutics offers Elamipretide.
Stealth BioTherapeutics has 8 investors. Key investors include CMBC Capital, Morningside, Atlantis Investment, BioVeda China Fund, and Kingdon Capital Management.
Stealth BioTherapeutics operates through Stealth Biotherapeutics Inc..
Yes. Stealth BioTherapeutics was acquired by Morningside in August 2022.